Individuals with human papillomavirus (HPV)-related disease remain at risk for subsequent
HPV infection and related disease after treatment of specific lesions. Prophylactic HPV …

Background The extent of cross-protection provided by currently licensed bivalent and
quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58 …

Anogenital warts (AGWs) rank among the most frequent sexually transmitted infections in
young adults. They are benign lesions, but they pose a significant economic cost to health …

Background For several decades, diagnoses of genital warts at genitourinary medicine
(GUM) clinics in England had been increasing. In 2008, a national human papillomavirus …

Specific adult populations known to be at high risk for human papillomavirus (HPV)-related
disease, such as men who have sex with men, are inconsistently included in national …

Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts (GW)
in women aged 14–23 years and to estimate the incidence of GW in the whole population …

Objectives To estimate the prevalence of, and describe risk factors for, genital warts (GWs) in
the British population, following the introduction of the bivalent (human papillomavirus (HPV) …

Objectives Data from a vaccine trial and from post-vaccine surveillance in the United
Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection …

Background The benefit-risk balance of vaccines is regularly debated by the public, but the
utility of media monitoring for regulatory bodies is unclear. A media monitoring study was …

Extensive multiple-age cohort human papillomavirus (HPV) vaccination has proved to be
highly effective. We aimed to determine the 8-year population impact of a female single-age …